T. Rowe Price Associates’s Viridian Therapeutics VRDN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$62.7M	Sell	3,206,035 -233,379	-7%	-$6.93M	0.01%	716
2025 Q4	$107M	Buy	3,439,414 +1,021,310	+42%	+$28M	0.01%	616
2025 Q3	$52.2M	Sell	2,418,104 -477,161	-16%	-$8.61M	0.01%	799
2025 Q2	$40.5M	Buy	2,895,265 +1,207,136	+72%	+$16.4M	﹤0.01%	784
2025 Q1	$22.8M	Buy	1,688,129 +361,318	+27%	+$6.15M	﹤0.01%	925
2024 Q4	$25.4M	Buy	1,326,811 +1,281,799	+2,848%	+$27.9M	﹤0.01%	934
2024 Q3	$1.02M	Buy	45,012 +593	+1%	+$9.7K	﹤0.01%	1960
2024 Q2	$578K	Buy	44,419 +13,050	+42%	+$181K	﹤0.01%	2134
2024 Q1	$550K	Buy	31,369 +5,429	+21%	+$105K	﹤0.01%	2171
2023 Q4	$565K	Sell	25,940 -585	-2%	-$9.23K	﹤0.01%	2126
2023 Q3	$407K	Buy	26,525 +2,580	+11%	+$49.2K	﹤0.01%	2212
2023 Q2	$570K	Buy	23,945 +1,286	+6%	+$33K	﹤0.01%	2062
2023 Q1	$577K	Sell	22,659 -2,235	-9%	-$71.7K	﹤0.01%	2045
2022 Q4	$727K	Buy	24,894 +7,340	+42%	+$169K	﹤0.01%	1954
2022 Q3	$361K	Buy	+17,554	New	+$316K	﹤0.01%	2295